Position in GNLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$145,200
-$426,326 QoQ
Shares Held
60,000
-54.2% QoQ
Ownership
0.134%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026683 Capital Management, LLC holds $329,314,446 across 63 Biotechnology names. GNLX ranks #63 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
355,000 | $37,417,000 | |
| 2 | WVE |
Wave Life Sciences Ltd.
|
4,900,000 | $35,525,000 | |
| 3 | IMUX |
Immunic, Inc.
|
2,450,000 | $27,195,000 | |
| 4 | ANAB |
Anaptysbio, Inc
|
625,000 | $23,108,312 | |
| 5 | MGTX |
MeiraGTx Holdings plc
|
2,450,000 | $21,217,000 | |
| 6 | PHAT |
Phathom Pharmaceuticals, Inc.
|
1,850,000 | $20,553,500 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
590,000 | $19,599,800 | |
| 8 | SRPT |
Sarepta Therapeutics, Inc.
|
750,000 | $16,320,000 |
All Filings in GNLX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $145,200 | 60,000 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $571,526 | 131,084 | Shares | Defined | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||